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Abstract: In search of new compounds with strong antiproliferative activity and simple 
molecular structure, we designed a novel series of agents based on the 2-amino-3-
alkoxycarbonyl/cyano-5-arylethylthiophene scaffold. The presence of the ethyl spacer between 
WKH¶¶-dimethoxyphenyl and the 5-position of the thiophene ring, as well as the number and 
location of methoxy substitutents on the phenyl ring, played a profound role in affecting the 
antiproliferative activity. Among the synthesized compounds, we identified the 2-amino-3-
cyano-[2-(2,5-dimethoxyphenyl)ethyl] thiophene 2c as the most promising derivative against 
a wide panel of cancer cell lines (IC50=17-130 nM). The antiproliferative activity of this 
compound appears to correlate well with its ability to inhibit tubulin assembly and the binding 
of colchicine to tubulin. Moreover 2c, as determined by flow cytometry, strongly induced 
arrest in the G2/M phase of the cell cycle, and annexin-V and propidium iodide staining 
indicate that cell death proceeds through an apoptotic mechanism that follows the intrinsic 
mitochondrial pathway. 
Keywords: tubulin, thiophene, anticancer agents, colchicine site, apoptosis. 
1. Introduction 
Microtubules are one of the three components of the cytoskeleton and are involved in a wide 
range of cellular functions critical for the life cycle of the cell. These include most notably cell 
division, where they form the mitotic spindle formation required for proper chromosomal 
separation.
1-3
 The microtubule system is also important in other fundamental cellular 
processes, such as regulation of motility, cell signaling, formation and maintenance of cell 
shape, secretion and intracellular transport.
4
 Research oriented toward the discovery of 
naturally occurring and synthetic molecules that bind to tubulin and disrupt microtubule 
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dynamics have attracted considerable attention in the last few decades, since microtubules are 
a validated and important pharmacological target in cancer chemotherapy.
5-8
  
Among synthetic small molecule tubulin inhibitors, Novartis Pharmaceuticals Corporation 
identified a new chemical entity as an anticancer agent, named SDZ LAP 977 (1, Chart 1). 
This compound contains two fragments, the methyl ester of salicylic acid and, at its 5-
position, D¶¶-dimethoxyphenylethyl moiety.9-10 Compound 1 is active at low micromolar 
concentrations as an antiproliferative agent against both human pancreatic tumor (MIA PaCa-
2) and epithelial carcinoma (A431) cells, blocking the cell cycle in mitosis through inhibition 
of tubulin polymerization. 
The classical bioisosteric equivalence between benzene and thiophene prompted us to 
synthesize a series of 2-amino-3,5-disubstituted thiophene derivatives with general formula 2, 
in which a 2-aminothiophene system bearing at its 3-position a methoxycarbonyl, 
ethoxycarbonyl or cyano group replaced the salicylic acid methyl ester of compound 1. In this 
regards, replacement of an hydroxyl with an amino group furnished encouraging results in 
terms of significantly increased cytotoxicity against many human cancer lines in a series of 
benzophenone-type CA-4 analogues named phenstatins.
11
 
.HHSLQJFRQVWDQW WKH¶¶-dimethoxyphenylethyl pharmacophore of 1 at the C-5 position of 
the thiophene ring, compounds 2a-c were designed in order to probe the importance of the 
substituent at the C-3 position, by the introduction of methoxycarbonyl (2a), ethoxycarbonyl 
(2b) and cyano (2c) groups. By the synthesis of 3,4-disubstituted derivatives 2d and 2e, we 
also evaluated the effect on activity caused by the concomitant presence of a methyl or 
ethoxycarbonyl at the C-4 position of the thiophene core in compounds 2a and 2b, 
respectively.  
 4 
Compounds 2f-m represent a second series of molecules in which the importance for 
antiproliferative activity caused by the absence (2m) or presence of a single methoxy 
VXEVWLWXWLRQ DW WKH ¶- RU ¶-position of the phenyl group of the phenylethyl moiety was 
evaluated (compounds 2fik and 2ghj, respectively).  
In order to study whether the ethyl spacer between the two aromatic ring systems was also 
beneficial for activity, we also synthesized compounds 2n-o, LQ ZKLFK WKH ¶¶-
dimethoxyphenyl nucleus was directly attached to the C-5 position of thiophene ring.  
We examined the efficacy of the newly synthesized compounds on a panel of cancer cell lines 
and, in addition, the mechanism of action of the most active compound was investigated in 
detail. 
Chart 1 should be inserted here 
2. Chemistry 
The general strategy for the preparation of compounds 2a-o is shown in Scheme 1. Crucial 
intermediates were identified as the thiophene derivatives 5a-e, obtained in a two step 
procedure starting from the 2-amino thiophenes 3a-e.
12
 These latter compounds were 
converted in good yields to the phthalimido derivatives 4a-e using phthalic anhydride in 
refluxing acetic acid. The subsequent regioselective bromination of 4a-e in a mixture of acetic 
acid and sodium acetate using bromine furnished intermediate 5-bromothiophenes 5a-e. 
Compounds 6a and 6b were prepared by palladium-mediated coupling chemistry of 2-
methoxycarbonyl and 2-cyano thiophenes 5a and 5c, respectively, ZLWK ¶ ¶-
dimethoxybenzeneboronic acid under heterogeneous conditions [Pd(PPh3)4, K2CO3] in 
refluxing toluene. Removal of the N-protected pthaloyl group was performed with hydrazine 
in refluxing ethanol to afford 2n and 2o. 
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The building block intermediates 5a-e, coupled by the Sonogashira cross-coupling reaction 
with the appropriate terminal arylacetylene
13
 in the presence a catalytic amount of 
PdCl2(PPh3)2 and CuI in a mixture of TEA and DMF, afforded the arylacetylenic 
intermediates 7a-m, which were reacted with hydrazine in refluxing ethanol to furnish 
compounds 8a-m. The reduced analogues 2a-m, characterized by the presence of a flexible 
ethyl linker, were prepared starting from derivatives 8a-m by catalytic hydrogenation of the 
acetylenic triple bond to ethyl over 10% Pd/C. 
Scheme 1 should be inserted here 
3. Biological Results and Discussion 
3.1. In vitro antiproliferative activities. Table 1 summarizes the growth inhibitory effects of 
derivatives 2a-o and reference compound 1 against murine leukemia (L1210), human cervix 
carcinoma (HeLa), murine mammary carcinoma (FM3A/0) and human T-lymphoblastoid 
(Molt4/C8 and CEM/0) cells. Only compounds 2a-c, with a common 2-amino-5-[2-(2,5-
dimethoxy-phenyl)-ethyl]-thiophene structure, were more active than 1 against FM3A cells. 
With the exception of this cell line, 2a was less active than 1 in the other cell lines, while 2b 
had potency similar to that of 1 in two of the three cell lines studied. In our hands, 1 was about 
30-fold less active in the FM3A cells than the other cell lines examined, and, with the 
exceptions of 2a-c, none of the other compounds we prepared was as active as 1 in any cell 
line where comparisons could be made. Aside from the extraordinary activity of 2c, in 
comparison with 1, a submicromolar IC50 value was only observed with compound 2g in 
CEM cells. We did examine a fifth cell line (Molt4/C8) with the new compounds, but not 1, 
and submicromolar IC50 values were obtained with 2a, 2f-h and 2j. However, it is only 2c that 
had especially noteworthy antiproliferative activity in these cell lines, ranging from 35 nM in 
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the CEM cells to 130 nM in the HeLa cells. It was therefore far superior to the lead compound 
1. Based on compounds 2a-e, this activity appears to derive from the nitrile substituent at 
position C-3 of the thiophene ring. Additional, much less active compounds with this 
substituent (2k-m and 2o) provide interesting SAR information. Removal of one (2k) or both 
(2m) methoxy groups from the phenyl ring lead to substantial losses of antiproliferative 
activity, greater with the removal of both methoxy groups. A single methoxy group at a 
different position (para to the ethylthiophene moiety, 2l) also resulted in a much less active 
compound. Finally, elimination of the two carbon bridge between the ring systems (2o) almost 
eliminated antiproliferative activity. 
In summary, using the biospheric thiophene ring to replace the second phenyl ring of 
compound 1, we synthesized a potent new agent with amino and nitrile substituents at 
positions C-2 and C-3, respectively. Thus far, additional manipulations of the basic structure 
of compound 2c have only resulted in much less active compounds. 
Table 1 should be inserted here 
3.2. Effect of compound 2c on a panel of human cancer cell lines. To further characterize 
the tumor cell growth inhibitory profile of 2c, it was tested against a panel of an additional 
twelve human cancer cell lines. These studies confirmed its excellent activity, with IC50 
values obtained ranging from 12 to 86 nM (Table 2). The greatest activity was observed with 
Jurkat, the least activity with MT4 both two T-leukemia cell lines. 
Table 2 should be inserted here 
3.3. Inhibition of tubulin polymerization and colchicine binding. To investigate whether 
the antiproliferative activity of the highly active 2c derived from an interaction with tubulin, 
2c and additional compounds were evaluated for their inhibition of tubulin polymerization 
 7 
(Table 3).
14 
For comparison, compound 1 was examined in contemporaneous experiments. In 
the assembly assay, compounds 2c was the most active compound (IC50 value 0.74 PM), with 
activity 3-fold greater than that of 1 (IC50, 2.0 PM). Compounds 2a and 2b inhibited tubulin 
assembly with IC50 values of 1.9 and 3.1 µM, respectively. The other compounds examined 
were much less active as inhibitors of tubulin assembly. Note that 2c had much greater 
antiproliferative activity than 1, 2a and 2b, despite the similar effects on tubulin assembly. 
Such discrepancies in antitubulin versus antiproliferative activity are not infrequently 
observed, but the reasons are usually uncertain, as is the case here. Among possible 
explanations is that we are using bovine brain tubulin in the former studies, and its 
composition in terms of tubulin isotypes differs significantly from that of different human 
cancer cell lines.
15
 
The most active compounds in the in vitro tubulin polymerization assay were also evaluated 
for their effects on the binding of [
3
H]colchicine to tubulin.
16
 In this assay, derivative 2c 
potently inhibited the binding of [
3
H]colchicine to tubulin, and with 84% inhibition was 1.5-
fold more active than 1, which in this experiment inhibited colchicines binding by 52%. 
Inhibition of colchicine binding by compounds 2a and 2b was also lower than inhibition by 
2c, but comparable to inhibition by 1. For the highly active 2c, a good correlation was 
observed between antiproliferative activity, inhibition of tubulin polymerization and inhibition 
of colchicine binding. These results indicate that an interaction with tubulin is a major cause 
of the antiproliferative activity of this group of compounds. 
Table 3 should be inserted here 
3.4. Molecular Modeling. A series of molecular modeling simulations were performed to 
investigate the structural basis of the findings described above. The in silico studies were 
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focused on understanding the role of the substitution pattern on the phenyl ring as well as the 
replacement of the ester with a nitrile group in the binding of these analogues to tubulin. 
Initially, we performed a series of molecular docking calculations, which resulted in a 
suggested binding mode for this class of compounds very similar to the one reported in 
literature for several other colchicines site compounds.
17
 In particular, all the compounds were 
placed with the phenyl ring in proximity of ECys241 and with the amino group within 
hydrogen-bond distance of ĮThr179. However, as shown in Fig. 1, the docking software also 
predicted virtually the same binding pose for inactive compounds like 2f, and therefore our 
initial modeling studies did not provide a plausible justification for the empirical data 
obtained. For this reason, we performed a set of molecular dynamics (MD) simulations on the 
complexes between tubulin and three representative compounds of the series 2a, 2c and 2f. 
The results obtained gave more detailed insight into a possible binding mechanism for these 
molecules. The most active compound in the series, 2c, was stable during the 3ns MD, with 
the phenyl ring always interacting with the ECys241 (see Supplementary Data) and forming a 
stable hydrogen bond with ĮThr179 (82% rate of formation). Furthermore, the 2-
aminothiophene moiety maintained a close contact with EAsn258 (Fig. 2). Compound 2a also 
maintained a close contact with ECys241, but the hydrogen bond with ĮThr179 was less 
stable (22% rate of formation). Interestingly, the interaction of 2a with EAsn258 seemed to be 
affected, possibly because of increased steric hindrance by the ester methyl group. Finally, in 
the case of 2f, the binding pose was significantly less stable (see Supporting Information). 
During the MD simulation, the compound moved away from both ECys241 and ĮThr179 
(12% rate of formation of the hydrogen bond with the amino group of 2f). The interaction 
with EAsn258 was also disrupted during the calculations. In summary, from the MD 
simulations it appears that the methoxy group in the meta position of the phenyl ring is 
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important in locking the compounds into the binding pocket, while the stability of the 
hydrogen bond of the 2-aminothiophene moiety with ĮThr179, supported by the interaction 
with EAsn258, is responsible for enhancing  the activity of 2c relative to 2a and 2f. 
Figures 1 and 2 should be inserted here 
3.5. Analysis of cell cycle effects of compound 2c. The effects of different concentrations of 
compound 2c, after 24 h of treatment on cell cycle progression were examined in HeLa cells 
(Figure 3, Panel A) and in Jurkat cells (Figure 3, Panel B). The compound caused a significant 
G2/M arrest in a concentration-dependent manner, with a rise in G2/M cells occurring at a 
concentration as low as 30 nM, while at higher concentrations more than 80% of the cells 
were arrested in G2/M, with a concomitant decrease of cells in the other phases of the cell 
cycle (G1 and S).  
We next studied the association between 2c-induced G2/M arrest and alterations in expression 
of proteins that regulate cell division. Cell arrest at the prometaphase/metaphase to anaphase 
transition is normally regulated by the mitotic checkpoint.
18
 The cdc2/cyclin B complex 
controls both entry into and exit from mitosis. Phosphorylation of cdc2 on Tyr15 and 
phosphorylation of cdc25C phosphatase on Ser216 negatively regulate the activation of the 
cdc2/cyclin B complex. 
Thus, dephosphorylation of these proteins is needed to activate the cdc2/cyclin B complex. 
cdc25C is a major phosphatase that dephosphorylates the site on cdc2 and 
autodephosphorylates itself. Phosphorylation of cdc25C directly stimulates both its 
phosphatase and autophosphatase activities, a condition necessary to activate cdc2/cyclin B on 
entry of cells into mitosis.
19-20
 As shown in Figure 3 (panel C) in HeLa cells, 2c at low 
concentrations (50 and 100 nM) caused a marked increase in cyclin B1 expression after both 
24 and 48 h treatments. In addition, slower migrating forms of phosphatase cdc25C appeared 
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at 24 h, indicating changes in the phosphorylation state of this protein, followed by the 
disappearance of both forms of cdc25C at 48 h. The phosphorylation of cdc25C directly 
stimulates its phosphatase activity, and this is necessary to activate cdc2/cyclin B on entry of 
cells into mitosis.
19,20
 In addition, we observed a dramatic de-phosphorylation of cdc2 
(Tyr15), just after 24 h of treatment, which should result in inhibition of formation of the 
cdc2/cyclinB complex. 
Figure 3 should be inserted here 
3.6. Compound 2c induces apoptosis. To characterize the mode of cell death induced by 2c, 
a biparametric cytofluorimetric analysis was performed using PI, which stains DNA and 
enters only dead cells, and fluorescent immunolabeling of the protein annexin-V, which binds 
to PS in a highly selective manner.21 Dual staining for annexin-V and with PI permits 
discrimination between live cells (annexin-V-/PI-), early apoptotic cells (annexin-V+/PI-), late 
apoptotic cells (annexin-V+/PI+) and necrotic cells (annexin-V-/PI+) (Figure 4, Panel A). As 
depicted in Figure 4 (Panel B), after 24 h of treatment with compound 2c at different 
concentrations, we observed a significant, accumulation of annexin-V positive cells in a 
concentration±dependent manner that further increased at 48 h (Panel C) even at the lowest 
concentration used (15 nM). 
Figure 4 should be inserted here 
3.7. Effect of 2c on mitochondrial depolarization and ROS generation. Mitochondria play 
an essential role in the propagation of apoptosis.
22
 It is well established that, at an early stage, 
apoptotic stimuli alter the mitochondrial transmembrane potential ('\mt). '\mt was 
monitored by the fluorescence of the dye JC-1. In untretated cells (high '\mt), JC-1 displays a 
red fluorescence (590 nm). This is caused by spontaneous and local formation of aggregates 
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that are associated with a large shift in emission. In contrast, when the mitochondrial 
membrane is depolarized (low '\mt), JC-1 forms monomers that emit at 530 nm. As shown in 
Figure 5 (Panel A), 2c in HeLa cells induced a time and concentration±dependent increase in 
the proportion of cells with depolarized mitochondria. 
Mitochondrial membrane depolarization is associated with mitochondrial production of 
ROS.
23
 Therefore, we investigated whether ROS production increased after treatment with 2c. 
We utilized two fluorescence indicators, HE and H2-DCFDA, as previously described.
24
 The 
results presented in Figure 5 (Panels B and C) showed that 2c induced the production of 
significant amounts of ROS in comparison with control cells, which agrees with the 
previously described dissipation of '\mt. Altogether, these results indicate that this compound 
induced apoptosis through the mitochondrial pathway.  
Figure 5 should be inserted here
 
3.8. Compound 2c induces caspase activation and reduced expression of anti-apototic 
proteins. Caspases, which are proteolytic enzymes, are the central executioners of apoptosis, 
and their activation is mediated by various inducers.25 Synthesized as proenzymes, caspases 
are themselves activated by specific proteolytic cleavage reactions. Caspases-2, -8, -9, and -10 
are termed apical caspases and are usually the first to be activated in the apoptotic process. 
Following their activation, they in turn activate effector caspases, in particular caspase-3.26 
Following treatment of HeLa cells with compound 2c (50 and 100 nM), we observed an early 
activation of caspase-9 at 24 h, followed at 48 h by activation of caspase-3 and of the caspase-
3 substrate PARP (Figure 6, Panel A). These results are in good agreement with the 
mitochondrial depolarization described above, indicating that 2c induces the apoptotic 
intrinsic (mitochondrial) apoptosis pathway. 
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We also examined whether the induction of apoptosis by 2c was associated with changes in 
the expression of two proteins of the Bcl-2 family (Bcl-2 and Mcl-1), since there is increasing 
evidence that they share the signaling pathways induced by antimicrotubule compounds.
27-29 
Our results showed (Figure 6, Panel B) that the expression of the anti-apoptotic proteins Bcl-2 
and Mcl-1 was remarkably reduced after a 24 h and disappeared after a 48 h treatment at both 
concentrations used. In addition, expression of the X-linked inhibitor of apoptosis protein 
(XIAP), a member of the apoptosis inhibitors protein family (IAP), was strongly reduced 
concomitant with caspase activation (Figure 6, Panel B), suggesting that 2c-induced apoptosis 
may also be mediated by XIAP down-regulation. 
Figure 6 should be inserted here 
4. Conclusions 
SDZ LAP 977 is an inhibitor of tubulin polymerization which consists of two segments, the 
PHWK\O HVWHU RI VDOLF\OLF DFLG DQG ¶¶-dimethoxybenzene, linked by an ethyl spacer. The 
VDOLF\OLFDFLGPHWK\OHVWHUDQG¶¶-dimethoxy benzene fragments were varied structurally to 
furnish a new series of molecules based on the 2-aminothiophene scaffold, in which 
substitution at the C-3 or C-5 positions play important roles in potency and selectivity against 
a panel of cancer cell lines. Replacement of salicylic acid methyl ester of compound 1 with a 
2-amino-3-cyanothiophene system resulted in the identification of a novel potent 
antiproliferative agent (2c) against a panel of human and murine tumor cell lines, with IC50 
values ranging from 35 to 130 nM. The antiproliferative activity of 2c was enhanced by 3-
230-fold with respect to 1 in four cell lines. 2c was also clearly superior to its 
methoxycarbonyl (2a) and ethoxycarbonyl (2b) analogues. Removing the ethyl spacer 
between the two aromatic rings of 2c to furnish derivative 2o resulted in a substantial 
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reduction of activity. We also demonstrated that the antiproliferative activity of 2c required 
the presence of the ¶¶-dimethoxyphenylethyl moiety. We identified tubulin as the molecular 
target of compounds 2a-c, since they inhibited tubulin assembly and the binding of colchicine 
to tubulin. In particular, derivative 2c was the most potent inhibitor of tubulin polymerization 
and of colchicine binding in this group of compounds. In keeping with tubulin as its target, 2c 
induced cell cycle arrest in the G2/M phase of the cell cycle. This mitotic arrest was 
accompanied by an increase of cyclin B expression and a decrease in intracellular levels of 
cdc2 (Tyr15). Our data demonstrated that 2c induced apoptosis through the intrinsic 
mitochondrial pathway with caspase activation. Moreover, the compound strongly reduced the 
expression of Bcl-2 and Mcl-1, an anti-apoptotic member of the Bcl-2 family, which recently 
has been reported to regulate sensitivity to antimitotic drugs.
29 
These findings indicate that 2c 
is endowed with high antiproliferative activity and should be further investigated to determine 
its therapeutic potential. 
5. Experimental Section 
5.1.Chemistry. 
5.1.1. Materials and Methods. 
1
H spectra were recorded on a Bruker AC 200 or a Varian 
400 Mercury Plus spectrometer. Chemical shifts (G) are given in ppm, and the spectra were 
recorded in appropriate deuterated solvents, as indicated. Positive-ion electrospray ionization 
(ESI) mass spectra were recorded on a double-focusing Finnigan MAT 95 instrument with BE 
geometry. Melting points (mp) were determined on a Buchi-Tottoli apparatus and are 
uncorrected. All products reported showed 
1
H NMR spectra in agreement with the assigned 
structures. The purity of tested compounds was determined by combustion elemental analyses 
conducted by the Microanalytical Laboratory of the Chemistry Department of the University 
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of Ferrara with a Yanagimoto MT-5 CHN recorder elemental analyzer. All tested compounds 
yielded data consistent with a purity of at least 95% as compared with the theoretical values. 
All reactions were carried out under an inert atmosphere of dry nitrogen, unless otherwise 
indicated. Standard syringe techniques were used for transferring dry solvents. Reaction 
courses and product mixtures were routinely monitored by TLC on silica gel (precoated F254 
Merck plates), and compounds were visualized with aqueous KMnO4. Flash chromatography 
was performed using 230-400 mesh silica gel and the indicated solvent system. Organic 
solutions were dried over anhydrous Na2SO4 ¶¶-dimethoxyphenylboronic acid and 
arylacetylenes are commercially available and used as received. All chemicals and reagents 
were purchased from Aldrich (Sigma-Aldrich) or Lancaster (Alfa Aesar, Johnson Matthey 
Company). 
5.2. General procedure A for the synthesis of compounds 4a-e. To a suspension of 
thiophene derivatives 3a-e (5 mmol) in acetic acid (30 mL) was added phthalic anhydride 
(890 mg, 6 mmol). After stirring for 18 h at reflux, the solvent was evaporated and the residue 
dissolved in CH2Cl2 (50 mL). The organic solution was washed with a saturated solution of 
NaHCO3 (15 mL), water (10 mL) and brine (10 mL). The organic layer was dried and 
evaporated, and the residue was purified by flash chromatography on silica gel or by 
crystallization with petroleum ether to afford 4a-e. 
5.2.1. Methyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-carboxylate (4a). 
Following general procedure A, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 4a as a white solid (56% yield); 
mp 147-149 °C.
 1
H-NMR (CDCl3) G: 3.72 (s, 3H), 7.36 (d, J=5.6 Hz, 1H), 7.53 (d, J=5.6 Hz, 
1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=288.3. 
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5.2.2. Ethyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-carboxylate (4b). 
Following general procedure A, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 4b as a pink solid (58% yield); 
mp 67-69 °C.
 1
H-NMR (CDCl3) G: 1.07 (t, J=7.0 Hz, 3H), 4.16 (q, J=7.0 Hz, 2H), 7.35 (d, 
J=5.6 Hz, 1H), 7.55 (d, J=5.6 Hz, 1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=302.2. 
5.2.3. 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-carbonitrile (4c). Following 
general procedure A, the crude residue purified by crystallization from ethyl ether, furnished 
4c as a green solid (88% yield); mp 165-167 °C.
 1
H-NMR (CDCl3) G: 7.29 (d, J=5.6 Hz, 1H), 
7.44 (d, J=5.6 Hz, 1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=255.1. 
5.2.4. Methyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-4-methylthiophene-3-
carboxylate (4d). Following general procedure A, the crude residue purified by crystallization 
from petroleum ether, furnished 4d as a white solid (74% yield); mp 129-130 °C.
 1
H-NMR 
(CDCl3) G: 2.46 (s, 3H), 3.68 (s, 3H), 7.02 (s, 1H), (m, 2H), (m, 2H). MS (ESI): 
[M+1]
+
=302.2. 
5.2.5. Diethyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3,4-dicarboxylate 
(4e). Following general procedure A, the crude residue purified by flash chromatography 
using ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 4e as a yellow oil (74% 
yield).
 1
H-NMR (CDCl3) G: 1.24 (m, 6H), 4.39 (m, 4H), (m, 2H), 7.93 (s, 1H), (m, 
2H). MS (ESI): [M+1]
+
=374.3. 
5.3. General procedure B for the preparation of compounds 5a-e. To an acetic acid 
solution (12 mL) of derivatives 4a-e (5 mmol) containing sodium acetate (451 mg, 5.5 mmol), 
bromine (800 mg, 0.36 mL, 5 mmol) was added dropwise with stirring at room temperature 
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over 5 min. After 1 h, acetic acid was removed under vacuo, and the crude residue was diluted 
with EtOAc (25 mL), washed successively with an aqueous 10% sodium thiosulphate solution 
(10 mL), a saturated solution of NaHCO3 (10 mL), water (5 mL) and brine (5 mL), and dried 
and concentrated. The resulting residue was purified by crystallization from petroleum ether 
or by column chromatography on silica gel. 
5.3.1. Methyl 5-bromo-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-
carboxylate (5a). Following general procedure B, the crude residue purified by crystallization 
from petroleum ether, furnished 5a as a grey solid (55% yield); mp 135-137 °C.
 1
H-NMR 
(CDCl3) G: 3.73 (s, 3H), 7.51 (s, 1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=366.0 
and 368.0. 
5.3.2. Ethyl 5-bromo-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-carboxylate 
(5b). Following general procedure B, the crude residue purified by flash chromatography 
using ethyl acetate:petroleum ether 1:9 (v:v) for elution, furnished 5b as a white solid (87% 
yield); mp 109-110 °C.
 1
H-NMR (CDCl3) G: 1.09 (t, J=7.2 Hz, 3H), 4.15 (q, J=7.2 Hz, 2H), 
7.52 (s, 1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=380.1 and 382.1. 
5.3.3. 5-Bromo-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-carbonitrile (5c). 
Following general procedure B, the crude residue purified by crystallization from petroleum 
ether, furnished 5c as a yellow solid (82% yield); mp 204-205 °C.
 1
H-NMR (CDCl3) G: 
(m, 2H), 8.00 (s, 1H), (m, 2H). MS (ESI): [M+1]+=333.0 and 335.0. 
5.3.4. Methyl 5-bromo-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-4-methylthiophene-3-
carboxylate (5d). Following general procedure B, the crude residue purified by crystallization 
from petroleum ether, furnished 5d as a grey solid (80% yield); mp 152-154 °C.
 1
H-NMR 
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(CDCl3) G: 2.42 (s, 3H), 3.68 (s, 3H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=380.1 
and 382.2. 
5.3.5. Diethyl 5-bromo-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3,4-
dicarboxylate (5e). Following general procedure B, the crude residue purified by 
crystallization from petroleum ether, furnished 5e as a white solid (75% yield), mp 101-103 
°C.
 1
H-NMR (CDCl3) G: 1.07 (t, J=7.4 Hz, 3H), 1.38 (t, J=7.2 Hz, 3H), 4.15 (q, J=7.4 Hz, 
2H), 4.39 (q, J=7.4 Hz, 2H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=452.1 and 454.1. 
5.4. General procedure C for the synthesis of compounds 6a and 6b. A mixture of 
thiophene derivatives 5a or 5c (0.5 mmol), K2CO3 (104 mg, 0.75 mmol, 1.5 equiv.), 2,5-
dimethoxyphenylboronic acid (182 mg, 1 mmol, 2 equiv.) and Pd(PPh3)4 (13.5 mg, 0.012 
mmol) in dry toluene (10 mL) was stirred at 100 °C under nitrogen for 18 h, cooled to room 
temperature, filtered through celite and the filtrate evaporated in vacuo. The residue was 
dissolved with dichloromethane (15 mL), and the resultant solution was washed sequentially 
with 5% NaHCO3 (5 mL), water (5 mL) and brine (5 mL). The organic layer was dried over 
Na2SO4, evaporated and the residue purified by flash column chromatography on silica gel. 
5.4.1. Methyl 5-(2,5-dimethoxyphenyl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-
thiophene-3-carboxylate (6a). Following general procedure C, the crude residue purified by 
flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 6a as 
a white solid (58% yield); mp 201-202 °C.
 1
H-NMR (CDCl3) G: 3.74 (s, 3H), 3.85 (s, 3H), 
3.89 (s, 3H), 6.93 (m, 2H), 7.22 (d, J=5.2 Hz, 1H), (m, 2H), s+(m, 2H). 
MS (ESI): [M+1]
+
=424.2. 
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5.4.2. 5-(2,5-Dimethoxyphenyl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)thiophene-3-
carbonitrile (6b). Following general procedure C, the crude residue purified by flash 
chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 6b as a 
yellow solid (55% yield); mp 205-207 °C.
 1
H-NMR (CDCl3) G: 3.86 (s, 3H), 3.89 (s, 3H), 
6.91 (m, 2H), 7.22 (d, J=5.2 Hz, 1H), (m, 2H), s+(m, 2H). MS (ESI): 
[M+1]
+
=391.2. 
5.5. General procedure D for the preparation of compounds 7a-m. Under inert and 
anhydrous conditions, a 10 mL Schlenk vessel was charged with the appropriate 
bromothiophene derivative 5a-e (1 mmol). The material was dissolved in a mixture of TEA-
DMF (1:1, 4 mL). The corresponding acetylene derivatives (2 mmol), CuI (20 mg, 0.1 mmol) 
and PdCl2(PPh3)2 (70 mg, 0.1 mmol) were then added to the solution, which was stirred at 80 
°C for 16 h. The mixture was cooled to room temperature and filtered through celite. The 
celite was rinsed with dichloromethane, and the filtrate was concentrated in vacuo. The 
residue was fractionated between water (5 mL) and dichloromethane (15 mL). The organic 
layer was washed with brine (5 mL) and dried over Na2SO4, and the solvent was evaporated. 
The crude material was purified by column chromatography on silica gel. 
5.5.1. Methyl 5-[(2,5-dimethoxyphenyl)ethynyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)-thiophene-3-carboxylate (7a). Following general procedure D, the crude residue purified 
by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 
7a as a yellow solid (58% yield); mp 60-62 °C.
 1
H-NMR (CDCl3) G: 3.74 (s, 3H), 3.80 (s, 
3H), 3.88 (s, 3H), 6.86 (s, 1H), 6.90 (d, J=2.8 Hz, 1H), 7.02 (d, J=2.8 Hz, 1H), 7.67 (s, 1H), 
(m, 2H), (m, 2H). MS (ESI): [M+1]+=448.2. 
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5.5.2. Ethyl 5-[(2,5-dimethoxyphenyl)ethynyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)-thiophene-3-carboxylate (7b). Following general procedure D, the crude residue purified 
by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 
7b as a yellow oil (48% yield).
 1
H-NMR (CDCl3) G: 1.12 (t, J=7.0 Hz, 3H), 3.81 (s, 3H), 3.88 
(s, 3H), 4.18 (q, J=7.0 Hz, 2H), 6.86 (s, 1H), 6.89 (d, J=2.8 Hz, 1H), 7.03 (d, J=2.8 Hz, 1H), 
7.69 (s, 1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=462.1. 
5.5.3. 5-[(2,5-Dimethoxyphenyl)ethynyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-
thiophene-3-carbonitrile (7c). Following general procedure D, the crude residue purified by 
flash chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 7c as 
a brown solid (54% yield); mp 156-158 °C.
 1
H-NMR (CDCl3) G: 3.80 (s, 3H), 3.88 (s, 3H), 
6.95 (m, 2H), 7.01 (s, 1H), 7.40 (s, 1H), (m, 2H), (m, 2H). MS (ESI): 
[M+1]
+
=415.2. 
5.5.4. Methyl 5-[(2,5-dimethoxyphenyl)ethynyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)-4-methylthiophene-3-carboxylate (7d). Following general procedure D, the crude 
residue purified by flash chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for 
elution, furnished 7d as an orange solid (52% yield); mp 63-65 °C.
 1
H-NMR (CDCl3) G: 2.60 
(s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 3.88 (s, 3H), 6.88 (m, 2H), 7.02 (s, 1H), (m, 2H), 
(m, 2H). MS (ESI): [M+1]+=462.2. 
5.5.5. Diethyl 5-[(2,5-dimethoxyphenyl)ethynyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)thiophene-3,4-dicarboxylate (7e). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7e as a yellow solid (61% yield), mp 91-92 °C.
 1
H-NMR (CDCl3) G: 1.14 (t, J=7.2 
Hz, 3H), 1.39 (t, J=7.2 Hz, 3H), 3.80 (s, 3H), 3.87 (s, 3H), 4.19 (q, J=7.2 Hz, 2H), 4.40 (q, 
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J=7.2 Hz, 2H), 6.88 (m, 2H), 7.00 (d, J=2.6 Hz, 1H), (m, 2H), (m, 2H). MS (ESI): 
[M+1]
+
=554.4. 
5.5.6. Methyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(2-methoxyphenyl) 
ethynyl]thiophene-3-carboxylate (7f). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7f as a yellow solid (59% yield); mp 140-141 °C.
 1
H-NMR (CDCl3) G: 3.73 (s, 3H), 
3.91 (s, 3H), 6.92 (m, 2H), 7.35 (m, 1H), 7.47 (dd, J =7.6 and 1.8 Hz, 1H), 7.65 (s, 1H), 
(m, 2H), (m, 2H). MS (ESI): [M+1]+=418.2. 
5.5.7. Methyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(4-methoxyphenyl) 
ethynyl]thiophene-3-carboxylate (7g). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7g as a yellow solid (52% yield); mp 170-172 °C.
 1
H-NMR (CDCl3) G: 3.73 (s, 3H), 
3.84 (s, 3H), 6.89 (d, J=8.8 Hz, 2H), 7.46 (d, J=8.8 Hz, 2H), 7.60 (s, 1H), (m, 2H), 
(m, 2H). MS (ESI): [M+1]+=418.1. 
5.5.8. Methyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(4-methoxy-2-methylphenyl) 
ethynyl]thiophene-3-carboxylate (7h). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7h as a brown solid (51% yield); mp 158-160 °C.
 1
H-NMR (CDCl3) G: 2.46 (s, 3H), 
3.73 (s, 3H), 3.82 (s, 3H), 6.75 (m, 2H), 7.39 (m, 1H), 7.59 (s, 1H), (m, 2H), (m, 
2H). MS (ESI): [M+1]
+
=432.1. 
5.5.9. Ethyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(2-methoxyphenyl) 
ethynyl]thiophene-3-carboxylate (7i). Following general procedure D, the crude residue 
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purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7i as a brown oil (53% yield).
 1
H-NMR (CDCl3) G: 1.11 (t, J=7.0 Hz, 3H), 3.91 (s, 
3H), 4.16 (q, J=7.0 Hz, 2H), 6.92 (m, 2H), 7.35 (m, 1H), 7.46 (m, 1H), 7.67 (s, 1H), (m, 
2H), (m, 2H). MS (ESI): [M+1]+=432.2. 
5.5.10. Methyl 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(4-methoxyphenyl) 
ethynyl]thiophene-3-carboxylate (7j). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7j as a yellow solid (56% yield); mp 139-140 °C.
 1
H-NMR (CDCl3) G: 1.06 (t, J=7.2 
Hz, 3H), 3.84 (s, 3H), 4.16 (q, J=7.2 Hz, 2H), 6.89 (d, J=8.8 Hz, 2H), 7.46 (d, J=8.8 Hz, 2H), 
7.62 (s, 1H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=432.1. 
5.5.11. 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(2-methoxyphenyl) 
ethynyl]thiophene-3-carbonitrile (7k). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 2:8 (v:v) for elution, 
furnished 7k as a brown solid (54% yield); mp 139-140 °C.
 1
H-NMR (CDCl3) G: 3.91 (s, 3H), 
6.95 (m, 2H), 7.36 (m, 3H), (m, 2H), (m, 2H). MS (ESI): [M+1]+=385.1. 
5.5.12. 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-[(4-methoxyphenyl) 
ethynyl]thiophene-3-carbonitrile (7l). Following general procedure D, the crude residue 
purified by flash chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for elution, 
furnished 7l as a brown solid (54% yield); mp 160-162 °C.
 1
H-NMR (CDCl3) G: 3.82 (s, 3H), 
6.88 (d, J=8.8 Hz, 2H), 6.95 (m, 2H), 7.31 (s, 1H), 7.37 (d, J=8.8 Hz, 2H), (m, 2H), 
(m, 2H). MS (ESI): [M+1]+=385.1. 
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5.5.13. 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-(phenylethynyl) thiophene-3-
carbonitrile (7m). Following general procedure D, the crude residue purified by flash 
chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 7m as a 
brown solid (43% yield); mp 169-171 °C.
 1
H-NMR (CDCl3) G: 7.39 (m, 4H), 7.52 (m, 2H), 
(m, 2H), (m, 2H). MS (ESI): [M+1]+=355.2. 
5.6. General procedure E for the synthesis of compounds 8a-m and 2n-o. A stirred 
suspension of a thiophene derivative 7a-m and 6a-b (1 mmol) and hydrazine monohydrate (60 
PL, 1.2 mmol, 1.2 equiv.) in abs. EtOH (10 mL) was refluxed for 1 h. The solvent was 
evaporated, and the residue was partitioned between dichloromethane (20 mL) and water (5 
mL). The separated organic phase, washed with brine (5 mL) and dried over Na2SO4, was 
concentrated under reduced pressure to obtain a residue that was purified by column 
chromatography. 
5.6.1. Methyl 2-amino-5-[(2,5-dimethoxyphenyl)ethynyl]thiophene-3-carboxylate (8a). 
Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 8a as a yellow solid (90% yield); 
mp 147-148 °C.
 1
H-NMR (CDCl3) G: 3.78 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 6.17 (bs, 2H), 
6.82 (s, 1H), 6.97 (m, 1H), 7.67 (s, 1H), s, 1H). MS (ESI): [M+1]+=317.1. 
5.6.2. Ethyl 2-amino-5-[(2,5-dimethoxyphenyl)ethynyl]thiophene-3-carboxylate (8b). 
Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 8b as a yellow oil (85% yield).
 
1
H-NMR (CDCl3) G: 1.35 (t, J=7.0 Hz, 3H), 3.78 (s, 3H), 3.86 (s, 3H), 4.29 (q, J=7.0 Hz, 2H), 
6.13 (bs, 2H), 6.83 (d, J=3.4 Hz, 1H), 6.84 (s, 1H), 6.98 (d, J=3.4 Hz, 1H), s, 1H). MS 
(ESI): [M+1]
+
=332.3. 
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5.6.3. 2-Amino-5-[(2,5-dimethoxyphenyl)ethynyl]thiophene-3-carbonitrile (8c). Following 
general procedure E, the crude residue purified, by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) for elution, furnished 8c as a brown solid (73% yield), mp 
122-124 °C.
 1
H-NMR (CDCl3) G: 3.78 (s, 3H), 3.86 (s, 3H), 4.93 (bs, 2H ), 6.85 (m, 2H), 6.96 
(m, 3H). MS (ESI): [M+1]
+
=285.1. 
5.6.4. Methyl 2-amino-5-[(2,5-dimethoxyphenyl)ethynyl]-4-methylthiophene-3-
carboxylate (8d). Following general procedure E, the crude residue purified by flash 
chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 8d as a 
yellow solid (77% yield); mp 100-102 °C.
 1
H-NMR (CDCl3) G: 2.46 (s, 3H), 3.78 (s, 3H), 
3.84 (s, 3H), 3.86 (s, 3H), 6.50 (bs, 2H), 6.83 (m, 2H), 6.98 (m, 1H). MS (ESI): 
[M+1]
+
=332.1. 
5.6.5. Diethyl 2-amino-5-[(2,5-dimethoxyphenyl)ethynyl]thiophene-3,4-dicarboxylate 
(8e). Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 8e as a yellow solid (78% yield), 
mp 103-104 °C.
 1
H-NMR (CDCl3) G: 1.32 (t, J=7.2 Hz, 3H), 1.38 (t, J=7.2 Hz, 3H), 3.78 (s, 
3H), 3.84 (s, 3H), 4.26 (q, J=7.0 Hz, 2H), 4.38 (q, J=7.0 Hz, 2H), 6.23 (bs, 2H), 6.83 (m, 2H), 
6.94 (d, J=2.0 Hz, 1H). MS (ESI): [M+1]
+
=404.2. 
5.6.6. Methyl-2-Amino-5-[(2-methoxyphenyl)ethynyl]thiophene-3-carboxylate (8f). 
Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 8f as a yellow oil (82% yield).
 
1
H-NMR (CDCl3) G: 3.81 (s, 3H), 3.89 (s, 3H), 6.12 (bs, 2H), 6.88 (m, 2H), 7.20 (s, 1H), 7.26 
(m, 1H), 7.42 (dd, J=7.4 and 1.4 Hz, 1H). MS (ESI): [M+1]
+
=288.2. 
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5.6.7. Methyl-2-amino-5-[(4-methoxyphenyl)ethynyl]thiophene-3-carboxylate (8g). 
Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 8g as a yellow solid (74% yield), 
mp 108-110 °C.
 1
H-NMR (CDCl3) G: 3.81 (s, 3H), 3.86 (s, 3H), 6.12 (bs, 2H), 6.85 (dd, J=8.8 
and 1.8 Hz, 2H), 7.14 (s, 1H), 7.40 (dd, J=8.6 and 1.8 Hz, 2H). MS (ESI): [M+1]
+
=288.2. 
5.6.8. Methyl-2-amino-5-[(4-methoxy-2-methylphenyl)ethynyl]thiophene-3-carboxylate 
(8h). Following general procedure E, the crude residue purified by flash chromatography 
using ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 8h as a brown solid (88% 
yield), mp 121-122 °C.
 1
H-NMR (CDCl3) G: 2.42 (s, 3H), 3.81 (s, 3H), 3.82 (s, 3H), 6.10 (bs, 
2H), 6.73 (m, 2H), 7.13 (s, 1H), 7.35 (d, J=8.6 Hz, 1H). MS (ESI): [M+1]
+
=302.2. 
5.6.9. Ethyl-2-amino-5-[(2-methoxyphenyl)ethynyl]thiophene-3-carboxylate (8i). 
Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 8i as a brown oil (52% yield).
 1
H-
NMR (CDCl3) G: 1.33 (t, J=7.2 Hz, 3H), 3.89 (s, 3H), 4.26 (q, J=7.2 Hz, 2H), 6.15 (bs, 2H), 
6.90 (m, 2H), 7.22 (s, 1H), 7.31 (m, 2H). MS (ESI): [M+1]
+
=302.1. 
5.6.10. Ethyl-2-amino-5-[(4-methoxyphenyl)ethynyl]thiophene-3-carboxylate (8j). 
Following general procedure E, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 8j as a yellow solid (89% yield), 
mp 90-92 °C.
 1
H-NMR (CDCl3) G: 1.33 (t, J=7.2 Hz, 3H), 3.81 (s, 3H), 4.26 (q, J=7.2 Hz, 
2H), 6.14 (bs, 2H), 6.84 (d, J=8.8 Hz, 2H), 7.16 (s, 1H), 7.36 (d, J=8.6 Hz, 2H). MS (ESI): 
[M+1]
+
=302.0. 
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5.6.11. 2-Amino-5-[(2-methoxyphenyl)ethynyl]thiophene-3-carbonitrile (8k). Following 
general procedure E, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) for elution, furnished 8k as a brown oil (74% yield).
 1
H-
NMR (CDCl3) G: 3.89 (s, 3H), 4.93 (bs, 2H ), 6.92 (m, 2H), 7.30 (m, 2H), 7.42 (dd, J=7.4 and 
1.6 Hz, 1H). MS (ESI): [M+1]
+
=255.1. 
5.6.12. 2-Amino-5-[(4-methoxyphenyl)ethynyl]thiophene-3-carbonitrile (8l). Following 
general procedure E, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) for elution, furnished 8l as a brown solid (73% yield), mp 
185-186 °C.
 1
H-NMR (CDCl3) G: 3.83 (s, 3H), 4.92 (bs, 2H), 6.87 (m, 3H), 7.41 (d, J=9.2 Hz, 
2H). MS (ESI): [M+1]
+
=255.0. 
5.6.13. 2-Amino-5-(phenylethynyl)thiophene-3-carbonitrile (8m). Following general 
procedure E, the crude residue purified by flash chromatography using ethyl acetate:petroleum 
ether 3:7 (v:v) for elution, furnished 8m as a yellow solid (82% yield), mp 173-174 °C.
 1
H-
NMR (CDCl3) G: 4.98 (bs, 2H), 6.91 (s, 1H), 7.39 (m, 5H). MS (ESI): [M+1]+=225.1. 
5.6.14. Methyl 2-amino-5-(2,5-dimethoxyphenyl)thiophene-3-carboxylate (2n). Following 
general procedure E, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 2:8 (v:v) for elution, furnished 2n as a white solid (63% yield); mp 
204-205 °C.
 1
H-NMR (CDCl3) G: 3.78 (s, 3H), 3.81 (s, 3H), 3.84 (s, 3H), 5.89 (bs, 2H), 6.77 
(dd, J=8.8 and 3.0 Hz, 1H), 6.90 (d, J=8.8 Hz, 1H), 7.09 (d, J=3.0 Hz, 1H), s, 1H). MS 
(ESI): [M+1]
+
=294.1. Anal. (C14H15NO4S) C, H, N.  
5.6.15. 2-Amino-5-(2,5-dimethoxyphenyl)thiophene-3-carbonitrile (2o). Following general 
procedure E, the crude residue purified by flash chromatography using ethyl acetate:petroleum 
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ether 3:7 (v:v) for elution, furnished 2o as a cream-colored solid (74% yield), mp 126-127 °C.
 
1
H-NMR (CDCl3) G: 3.81 (s, 3H), 3.86 (s, 3H), 6.56 (bs, 2H), 6.78 (dd, J=8.8 and 3.0 Hz, 
1H), 6.84 (d, J=8.8 Hz, 1H), 7.11 (m, 2H). MS (ESI): [M+1]
+
=260.3. Anal. (C13H12N2O2S) C, 
H, N. 
5.7. General procedure F for the synthesis of compounds 2a-m. A solution of 
phenylalkynyl derivative 9a-m (0.5 mmol) in EtOH (10 mL) was hydrogenated over 50 mg of 
10% Pd/C at 50 p.s.i for 4 h. The catalyst was removed by filtration, and the filtrate was 
concentrated under reduced pressure to furnish a residue that was purified by column 
chromatography on silica gel. 
5.7.1. Methyl 2-amino-5-[2-(2,5-dimethoxyphenyl)ethyl]thiophene-3-carboxylate (2a). 
Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 2a as a yellow solid (77% yield); 
mp 107-108 °C.
 1
H-NMR (CDCl3) G: 2.86 (s, 4H), 3.75 (s, 3H), 3.79 (s, 6H), 5.80 (bs, 2H), 
6.71 (m, 4H). MS (ESI): [M+1]
+
=322.2. Anal. (C16H19NO4S) C, H, N.  
5.7.2. Ethyl 2-amino-5-[2-(2,5-dimethoxyphenyl)ethyl]thiophene-3-carboxylate (2b). 
Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 2b as a yellow oil (86% yield).
 
1
H-NMR (CDCl3) G: 1.34 (t, J=7.2 Hz, 3H), 2.86 (s, 4H), 3.75 (s, 3H), 3.79 (s, 3H), 4.26 (q, 
J=7.2 Hz, 2H), 5.79 (bs, 2H), 6.72 (m, 4H). MS (ESI): [M+1]
+
=336.1. Anal. (C17H21NO4S) C, 
H, N. 
5.7.3. 2-Amino-5-[2-(2,5-dimethoxyphenyl)ethyl]thiophene-3-carbonitrile (2c). Following 
general procedure F, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) for elution, furnished 2c as a yellow solid (70% yield), mp 
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89-91 °C.
 1
H-NMR (CDCl3) G: 2.86 (s, 4H), 3.77 (s, 6H), 4.62 (bs, 2H), 6.37 (s, 1H), 6.72 (m, 
3H). MS (ESI): [M+1]
+
=289.1. Anal. (C15H16N2O2S) C, H, N.  
5.7.4. Methyl 2-amino-5-[2-(2,5-dimethoxyphenyl)ethyl]-4-methylthiophene-3-
carboxylate (2d). Following general procedure F, the crude residue purified by flash 
chromatography using ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 2d as a 
yellow oil (82% yield).
 1
H-NMR (CDCl3) G: 2.12 (s, 3H), 2.79 (s, 4H), 3.77 (s, 3H), 3.80 (s, 
3H), 3.81 (s, 3H), 5.93 (bs, 2H), 6.72 (m, 3H). MS (ESI): [M+1]
+
=336.2. Anal. (C17H21NO4S) 
C, H, N.  
5.7.5. Diethyl 2-amino-5-[2-(2,5-dimethoxyphenyl)ethyl]thiophene-3,4-dicarboxylate 
(2e). Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 2b as a yellow oil (81% yield).
 
1
H-NMR (CDCl3) G: 1.24 (t, J=7.2 Hz, 3H), 1.34 (t, J=7.2 Hz, 3H), 2.86 (s, 4H), 3.74 (s, 6H), 
4.22 (q, J=7.2 Hz, 2H), 4.26 (q, J=7.2 Hz, 2H), 6.02 (bs, 2H), 6.71 (m, 3H). MS (ESI): 
[M+1]
+
=408.3. Anal. (C20H25NO6S) C, H, N.  
5.7.6. Methyl 2-amino-5-[2-(2-methoxyphenyl)ethyl]thiophene-3-carboxylate (2f). 
Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 2f as a yellow oil (87% yield).
 
1
H-NMR (CDCl3) G: 2.87 (s, 4H), 3.78 (s, 3H), 3.82 (s, 3H), 5.83 (bs, 2H), 6.66 (s, 1H), 6.88 
(m, 2H), 7.15 (m, 2H). MS (ESI): [M+1]
+
=291.1. Anal. (C15H17NO3S) C, H, N.  
5.7.7. Methyl 2-amino-5-[2-(4-methoxyphenyl)ethyl]thiophene-3-carboxylate (2g). 
Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 2g as a colorless oil (>95% 
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yield).
 1
H-NMR (CDCl3) G: 2.87 (s, 4H), 3.78 (s, 3H), 3.83 (s, 3H), 5.81 (bs, 2H), 6.62 (s, 
1H), 6.82 (d, J=8.6 Hz, 2H), 7.09 (d, J=8.6 Hz, 2H). MS (ESI): [M+1]
+
=291.1. Anal. 
(C15H17NO3S) C, H, N. 
5.7.8. Methyl 2-amino-5-[2-(4-methoxy-2-methylphenyl)ethyl]thiophene-3-carboxylate 
(2h). Following general procedure F, the crude residue purified by flash chromatography 
using ethyl acetate:petroleum ether 3:7 (v:v) for elution, furnished 2h as a yellow solid (71% 
yield), mp 110-112 °C.
 1
H-NMR (CDCl3) G: 2.30 (s, 3H), 2.82 (s, 4H), 3.81 (s, 6H), 5.85 (bs, 
2H), 6.70 (m, 3H), 7.06 (d, J=8.0 Hz, 1H). MS (ESI): [M+1]
+
=306.2. Anal. (C16H19NO3S) C, 
H, N.  
5.7.9. Ethyl 2-amino-5-[2-(2-methoxyphenyl)ethyl]thiophene-3-carboxylate (2i). 
Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 2i as a colorless oil (>95% yield).
 
1
H-NMR (CDCl3) G: 1.33 (t, J=7.0 Hz, 3H), 2.87 (s, 4H), 3.83 (s, 3H), 4.25 (q, J=7.0 Hz, 2H), 
5.80 (bs, 2H), 6.66 (s, 1H), 6.67 (s, 1H), 6.87 (m, 2H), 7.25 (m, 1H). MS (ESI): 
[M+1]
+
=306.2. Anal. (C16H19NO3S) C, H, N.  
5.7.10. Ethyl 2-amino-5-[2-(4-methoxyphenyl)ethyl]thiophene-3-carboxylate (2j). 
Following general procedure F, the crude residue purified by flash chromatography using 
ethyl acetate:petroleum ether 2:8 (v:v) for elution, furnished 2j as a colorless oil (>95% yield).
 
1
H-NMR (CDCl3) G: 1.33 (t, J=7.2 Hz, 3H), 2.84 (s, 4H), 3.79 (s, 3H), 4.23 (q, J = 7.2 Hz, 
2H), 5.81 (bs, 2H), 7.64 (s, 1H), 6.82 (d, J=8.6 Hz, 2H), 7.10 (d, J=8.6 Hz, 2H). MS (ESI): 
[M+1]
+
=306.2. Anal. (C16H19NO3S) C, H, N.  
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5.7.11. 2-Amino-5-[2-(2-methoxyphenyl)ethyl]thiophene-3-carbonitrile (2k). Following 
general procedure F, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) for elution, furnished 2k as a brown oil (52% yield).
 1
H-
NMR (CDCl3) G: 2.88 (s, 4H), 3.84 (s, 3H), 4.64 (bs, 2H), 6.36 (s, 1H), 6.89 (m, 2H), 7.17 (m, 
3H). MS (ESI): [M+1]
+
=259.2. Anal. (C14H14N2OS) C, H, N.  
5.7.12. 2-Amino-5-[2-(4-methoxyphenyl)ethyl]thiophene-3-carbonitrile (2l). Following 
general procedure F, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) for elution, furnished 2l as a brown solid (70% yield), mp 
145-147 °C.
 1
H-NMR (CDCl3) G: 2.85 (s, 4H), 3.80 (s, 3H), 4.62 (bs, 2H ), 6.34 (s, 1H), 6.83 
(d, J=8.8 Hz, 2H), 7.08 (d, J=8.8 Hz, 2H). MS (ESI): [M+1]
+
=259.3. Anal. (C14H14N2OS) C, 
H, N. 
5.7.13. 2-Amino-5-phenylethylthiophene-3-carbonitrile (2m). Following general procedure 
F, the crude residue purified by flash chromatography using ethyl acetate:petroleum ether 3:7 
(v:v) for elution, furnished 2m as an orange solid (65% yield), mp 127-129 °C.
 1
H-NMR 
(CDCl3) G: 2.90 (s, 4H), 4.63 (bs, 2H), 6.35 (s, 1H), 7.23 (m, 5H). MS (ESI): [M+1]+=229.1. 
Anal. (C13H12N2S) C, H, N. 
5.8. Biology Experiments 
5.8.1. Antiproliferative assays. Cancer cells were suspended at 300,000-500,000 cells/mL of 
culture medium, and 100 µL of a cell suspension was added to 100 µL of an appropriate 
dilution of the test compounds in wells of 96-well microtiter plates. After incubation at 37 °C 
for 48 h, cell number was determined using a Coulter counter. The IC50 was defined as the 
compound concentration required to inhibit cell proliferation by 50%. 
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5.8.2. Effects on tubulin polymerization and on colchicine binding to tubulin. To evaluate 
the effect of the compounds on tubulin assembly in vitro,14 varying concentrations of 
compounds were preincubated with 10 P0ERYLQHEUDLQWXEXOLQLQJOXWDPDWHEXIIHUDWÛ&
DQGWKHQFRROHGWRÛ&$IWHUDGGLWLRQRIP0*73WKHPL[WXUHVZHUH transferred to 0 qC 
cuvettes in a recording spectrophotometer and warmed to 30 °C. Tubulin assembly was 
followed turbidimetrically at 350 nm. The IC50 was defined as the compound concentration 
that inhibited the extent of assembly by 50% after a 20 min incubation. The capacity of the 
test compounds to inhibit colchicine binding to tubulin was measured as described,16 except 
that the reaction mixtures contained 1 PM tubulin, 5 PM [3H]colchicine and 5 PM test 
compound. 
5.8.3. Molecular Modeling. All molecular modeling studies were performed on a MacPro 
dual 2.66GHz Xeon running Ubuntu 10. The tubulin structure was downloaded from the PDB 
data bank (http://www.rcsb.org/ - PDB code: 3HKC).30 The 3HKC structure was chosen based 
on the structural similarities of the co-crystallized ligand present in this complex over the 
ligands present in other tubulin structures available.17 Hydrogen atoms were added to the 
protein, using the Protonate3D function of Molecular Operating Environment (MOE).31 
Ligand structures were built with MOE and minimized using the MMFF94x forcefield until a 
RMSD gradient of 0.05 kcal mol-1 Å-1 was reached. The docking simulations were performed 
using PLANTS.32 Molecular dynamics was performed with the Gromacs 4.533 with the 
Amber99 force field. The structure was solvated using TIP3P water molecules, providing a 
minimum of 9.0 Å of water between the protein surface and any periodic box edge. The 
system was neutralized, minimized and then a position restrain dynamics simulation was 
carried out for 150 ps. The production simulation was conducted for 3 ns at 298 K using a 
 31 
NPT environment. Inhibitors were parameterized by Antechamber of AmberTool 1.5.34 
Trajectories analysis were carried out by VMD.35 
5.8.4. Flow cytometric analysis of cell cycle distribution. For flow cytometric analysis of 
DNA content, 5x105 HeLa cells in exponential growth were treated with different 
concentrations of the test compounds for 24 or 48 h. After the incubation period, the cells 
were collected, centrifuged and fixed with ice-cold ethanol (70%). The cells were then treated 
with lysis buffer containing RNAse A and 0.1% Triton X-100, and then stained with PI. 
Samples were analyzed on a Cytomic FC500 flow cytometer (Beckman Coulter). DNA 
histograms were analyzed using MultiCycle£ for Windows (Phoenix Flow Systems). 
5.8.5. Annexin-V assay. Surface exposure of PS on apoptotic cells was measured by flow 
cytometry with a Coulter Cytomics FC500 (Beckman Coulter) by adding annexin-V-FITC to 
FHOOV DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV $QQH[LQ-V Fluos, Roche Diagnostic). 
Simultaneously, the cells were stained with PI. Excitation was set at 488 nm, and the emission 
filters were at 525 and 585 nm, respectively, for FTIC and PI. 
5.8.6. Assessment of mitochondrial changes. The mitochondrial membrane potential was 
measured with the lipophilic cationic dye JC-1 (Molecular Probes), as described.24 The 
production of ROS was measured by flow cytometry using either HE (Molecular Probes) or 
H2DCFDA (Molecular Probes), as previously described.24  
5.8.7. Western Blot Analysis. HeLa cells were incubated in the presence of test compounds 
and, after different times, were collected, centrifuged and washed two times with ice cold 
phosphate-buffered saline (PBS). The pellet was then resuspended in lysis buffer containing 
T-PER Reagent (Pierce, Milano Italy), sodium chloride (300 mM), sodium orthovanadate (1 
mM), AEBSF, (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (2 mM), Aprotinin 
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(1 µg/ml), Pepstatin A (5 µg/ml), Leupeptin (1 µg/ml). After the cells were lysed on ice for 30 
min, lysates were centrifuged at 15000 x g at 4 °C for 10 min. The protein concentration in the 
supernatant was determined using the BCA protein assay reagents (Pierce, Italy). Equal 
amounts of protein (20 µg) were resolved using SDS-PAGE (7.5-15 % acrylamide gels) and 
transferred to PVDF Hybond-p membrane (GE Healthcare). Membranes were blocked with I-
block (Tropix), the membrane being gently rotated overnight at 4 qC. Membranes were then 
incubated with primary antibodies against Bcl-2, Mcl-1, Xiap, PARP, cleaved caspase-9, p-
cdc2Tyr15, cdc25c (Cell Signaling), caspase-3 (Alexis), F\FOLQ%8SVWDWHRUȕ-actin (Sigma-
Aldrich) for 2 h at room temperature. Membranes were next incubated with peroxidase-
labeled secondary antibodies for 60 min. All membranes were visualized using ECL Advance 
(GE Healthcare) and exposed to Hyperfilm MP (GE Healthcare). To ensure equal protein 
loading, each membrane was stripped and reprobed with anti-E-actin antibody. 
5.8.8. Statistical Analysis. Unless indicated otherwise, results are presented as mean ± S.E.M. 
The differences between different treatments were analyzed using the two-VLGHG6WXGHQW¶Vt test. 
P values less than 0.05 were considered significant. 
Supplementary data available. Molecular modeling studies (Figures 1-4s). Elemental 
analyses of compounds 2a-o. Supplementary data associated with this article can be found in 
the online version. 
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Abbreviations. Pd(PPh3)4, tetrakis (triphenylphosphine)palladium; K2CO3, potassium 
carbonate; PdCl2(PPh3)2, bis(triphenylphosphine)-palladium chloride; CuI, cuprous iodide; 
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TEA, triethylamine; DMF, N, 1¶-dimethylformamide; 10% Pd/C, 10% palladium on charcoal; 
SAR, structure-activity relationships; PI, propidium iodide; PS, phospholipid 
phosphatidylserine; JC-1, ¶¶-tetrachloro-¶¶-tetraethylbenzimidazolcarbocyanine; 
ROS, reactive oxygen species; HE, hydroxyethidine; H2DCFDA, 2,7-
dichlorodihydrofluorescein; PARP, poly-ADP-ribose polymerase; SDS-PAGE, sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. 
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Table 1. In vitro inhibitory effects of compounds 1 and 2a-o on proliferation of murine 
leukemia (L1210), murine mammary carcinoma (FM3A/0), human cervix carcinoma (HeLa) 
and human T-leukemia (Molt4/C8 and CEM) cells
 
 
Compound IC50±S.D (PM)a 
L1210 FM3A/0 Molt4/C8 CEM/0 HeLa 
2a 1.8±0.1 2.3±0.6 0.42±0.11 1.4±0.2 0.77±0.17 
2b 1.2±0.4 1.9±0.5 1.1±0.1 0.40±0.15 0.31±0.00 
2c 0.064±0.005 0.056±0.004 0.058±0.006 0.035±0.001 0.13±0.06 
2d 46±3.2 44±8.1 47±16 30±3.2 35±7.1 
2e 34±3.2 33±9.1 24±2.2 20±6.3 11±3.5 
2f 17±5.3 34±5.6 0.81±0.09 1.2±0.1 15±1.3 
2g 11±1.2 67±26 0.27±0.08 0.62±0.04 36±6.4 
2h 248±40 45±16 0.27±0.27 1.3±0.1 105±68 
2i 40±0.2 53±7.2 6.9±0.8 20±4.3 45±6.2 
2j 20±10 48±5.2 0.34±0.50 1.9±0.9 39±0.2 
2k 15±4.1 22±3.1 2.0±0.2 6.8±0.2 7.8±2.1 
2l 14±4.2 31±27 1.4±0.8 7.2±4.2 19±13 
2m 40±6.1 62±3.2 8.5±3.4 32±7.1 35±3.1 
2n 50±5.2 52±1.0 28±6.2 30±2.2 37±6.1 
2o 76±3.2 n.d. n.d. 12±3.1 71±20 
1 0.36±0.04 13±0.2 n.d. 0.44±0.01 0.41±0.08 
a
IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the 
IC50±SD from the dose-response curves of at least three independent experiments. 
n.d.= not determined. 
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Table 2. Effect of compound 2c on growth of different human cancer cell lines 
 
Cell type Cell line IC50±S.D (PM)a 
T-cell lymphoma Sup-T1 0.017±0.012 
T-Leukemia MT2 0.027±0.001 
T-Leukemia C8166 0.021±0.009 
T-Leukemia Jurkat 0.012±0.008 
T-cell lymphoma HUT78 0.062±0.019 
T-Leukemia MT4 0.086±0.048 
Non-Hodgkin leukemia/B-cell 
lymphoma 
Raji 0.064±0.025 
Osteosarcoma HOS, OST TK
-
 0.024±0.013 
Mammary carcinoma MCF-7 0.025±0.001 
Colon carcinoma  HT29 0.046±0.012 
Glioma  U87 0.038±0.008 
Prostate  DU145 0.061±0.016 
Prostate  PC-3 0.025±0.013 
a
IC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the 
IC50±SD from the dose-response curves of at least three independent experiments. 
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Table 3. Inhibition of tubulin polymerization and colchicine binding by compounds 1, 2a-c, 
2f-h and 2j. 
 
Compound 
Tubulin assembly
a 
IC50±S.D (PM) 
Colchicine binding 
b 
% ±S.D 
2a 1.9r0.02 52r0.9 
2b 3.1r0.2 46r0.9 
2c 0.74r0.06 84r5 
2f >20 n.d. 
2g 10r0.7 n.d. 
2h >20 n.d. 
2j 16r1 n.d. 
1 2.0r0.06 52r4 
a
 Inhibition of tubulin polymerization. Tubulin was at 10 PM. 
b
 Inhibition of [
3
H]colchicine binding. Tubulin, colchicine and tested compound were at 1, 5 and 5 PM, 
respectively. 
a,b
 Values are mean±S.D of four separate experiments.  
n.d.=not determined. 
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Figure Legends. 
Figure 1. Docking pose on E-tubulin of 2a, 2c and 2f, with carbon atoms indicated in green, 
cyan, and brown, respectively. The co-crystallised ligand is represented with carbon atom 
colored in purple. Amino acid carbons are in grey, with the important ECys241 and ĮThr179 
bolder than the other residues. Colors of other atoms: sulphur, yellow; nitrogen, blue; oxygen, 
red. Hydrogen atoms are not shown. 
Figure 2. Binding pose on E-tubulin of 2c after MD simulation. Colors of all atoms are as in 
Figure 1. 
Figure 3. (A and B). Effect of compound 2c on cell cycle distribution of HeLa (A) and Jurkat 
cells (B). Cells were treated with different concentrations of 2c ranging from 15 to 250 nM for 
24 h. Then the cells were fixed and stained with PI to analyze DNA content by flow 
cytometry. Data are presented as mean r SEM of three independent experiments. (C). Effect 
of 2c on G2/M regulatory proteins. HeLa cells were treated for 24 or 48 h with the indicated 
concentration of 2c. The cells were harvested and lysed for the detection of cyclin B, p-
cdc2
Y15
 and cdc25C expression by western blot analysis. To confirm equal protein loading, 
each membrane was stripped and reprobed with anti-E-actin antibody. 
Figure 4. (A). Representative dot plots of HeLa cells treated with 2c (62 nM) for 24 or 48 h 
and analyzed by flow cytometry after double staining of the cells with annexin-V-FITC and 
PI. (B and C). Percentage of cells found in the different regions of the biparametric histograms 
obtained from cytofluorimetric analysis, after incubation with 2c for 24 (Panel B) or 48 h 
(Panel C), at the indicated concentrations. 
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Figure 5. Assessment of mitochondrial dysfunction after treatment of HeLa cells with 
compound 2c. (A). Induction of loss of mitochondrial membrane potential ('\mt ) after 24 or 
48 h incubations with compound 2c at the indicated concentrations. (B and C) Mitochondrial 
production of ROS in HeLa cells following treatment with compound 2c. After the 24 or 48 h 
incubations, cells were stained with H2-DCFDA (B) or HE (C). Data are expressed as mean ± 
S.E.M. for three independent experiments.  
Figure 6. (A). Western blot analysis of cleaved caspase-3, cleaved caspase-9 and poly (ADP-
ribose) polymerase (PARP) after treatment of HeLa cells with 2c at the indicated 
concentrations and for the indicated times. (B). Western blot analysis of Bcl-2, Mcl-1 and 
XIAP after treatment of HeLa cells with 2c at the indicated concentrations and for the 
indicated times. To confirm equal protein loading, each membrane was stripped and reprobed 
with anti-E-actin antibody. 
 
 
 42 
 
 
 
 
 
Figure 1.  
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Chart 1. Chemical structures of SDZ LAP 977 (1) and 2-aminothiophene derivatives 2a-o 
 
CO2Me
OHOMe
OMe
1 (SDZ LAP 977)
S NH2
R1R2OMe
OMe
2a, R1=CO2Me, R2=H
2b, R1=CO2Et, R2=H
2c, R1=CN, R2=H
2d, R1=CO2Me, R2=Me
2e, R1=R2=CO2Et
2a-e
S NH2
R1
2f-m
R2
R3
2f, R1=CO2Me, R2=OMe, R3=H
2g, R1=CO2Me, R2=H, R3=OMe
2h, R1=CO2Me, R2=Me, R3=OMe
2i, R1=CO2Et, R2=OMe, R3=H
2j, R1=CO2Et, R2=H, R3=OMe
2k, R1=CN, R2=OMe, R3=H
2l, R1=CN, R2=H, R3=OMe
2m, R1=CN, R2=R3=H
S NH2
R1
2n-o
2n, R1=CO2Me
2o, R1=CN
OMe
OMe
1
2
34
5
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Scheme 1 
 
S NH2
R1R2
3a-e
3-5a, R1=CO2Me, R2=H
3-5b, R1=CO2Et, R2=H
3-5c, R1=CN, R2=H
3-5d, R1=CO2Me, R2=Me
3-5e, R1=R2=CO2Et
a
S N
R1R2
O
O
b
S N
R1R2
O
O
Br
4a-e
5a-e
S N
R1
O
O
c OMe
OMe
6a, R1=CO2Me
6b, R1=CN
d
S NH2
R1
2n-o
2n, R1=CO2Me
2o, R1=CN
OMe
OMe
6a-b
S N
R1
O
O
S NH2
R1
e
7a-m
d
8a-m 2a-m
R3
R4
R2
R5
S NH2
R1
R3
R4
R2
R5
R2
R3
R4
R5
7-8a, 2a, R1=CO2Me, R2,4=H, R3,5=OMe
7-8b, 2b, R1=CO2Et, R2,4=H, R3,5=OMe
7-8c, 2c, R1=CN, R2=H, R2,4=H, R3,5=OMe
7-8d, 2d, R1=CO2Me, R2=Me, R4=H, R3,5=OMe
7-8e, 2e, R1=R2=CO2Et, R4=H, R3,5=OMe
7-8f, 2f, R1=CO2Me, R2,4-5=H, R3=OMe
7-8g, 2g, R1=CO2Me, R2-3,5=H, R4=OMe
7-8h, 2h, R1=CO2Me, R2,5=H, R3=Me, R4=OMe
7-8i, 2i, R1=CO2Et, R2,4-5=H, R3=OMe
7-8j, 2j, R1=CO2Et, R2-3,5=H, R4=OMe
7-8k, 2k, R1=CN, R2,4-5=H, R3=OMe
7-8l, 2l, R1=CN, R2-3,5=H, R4=OMe
7-8m, 2m, R1=CN, R2-5=H
f
Reagents.a: phthalic anhydride, AcOH; b: Br2, AcOH-AcONa; c: 2',5'-(OMe)2C6H4B(OH)2, Pd(PPh3)4, 
K2CO3, PhCH3, 100 °C, 18 h from 5a and 5c,; d: NH2NH2, EtOH; e. appropriate arylacetylene,  
PdCl2(PPh3)2, CuI, TEA-DMF (1:1, v/v), 80 °C; f: H2, 10% Pd/C, EtOH.   
 
